Aandeel DTIL PRECISION BIOSCIENCES, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Precision BioSciences, Inc.

Aandelen

DTIL

US74019P2074

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 27-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
9,42 USD -2,59% Intraday-grafiek van Precision BioSciences, Inc. -3,58% -13,97%
12/06 Transcript : Precision BioSciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM
05/06 Precision Biosciences, Inc. Presenteert nieuwe preklinische veiligheidsgegevens voor de klinische kandidaat PBGENE-HBV op het European Association for the Study of the Liver Congress CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress
Certain Stock Options of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.
Certain Common Stock of Precision BioSciences, Inc. are subject to a Lock-Up Agreement Ending on 31-MAY-2024.
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Precision BioSciences: Q1 Earnings Snapshot
Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $17.6M, vs. Street Est of $6.02M
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
Precision BioSciences, Inc. announced that it has received $0.3 million in funding
Precision BioSciences to Report First Quarter Results on May 13, 2024
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers DTIL
  4. Nieuws Precision BioSciences, Inc.
  5. Andere talen